Navigation Links
Mobile phone use not linked to increased risk of glioma brain tumours

ude headaches and feelings of nausea. The causes of these tumours are currently unknown.

The study was conducted between 1 December 2000 and 29 February 2004 and included people living in the Thames region, southern Scotland, Trent, the West Midlands and West Yorkshire.

966 people with glioma brain tumours (cases) and 1716 healthy volunteers (controls) were interviewed about their previous mobile phone use history including how long they had used mobile phones, the number and duration of the calls they made and what make and model of phone they had used.


'"/>

Source:BMJ-British Medical Journal


Page: 1 2

Related biology news :

1. Mobile DNA part of evolutions toolbox
2. Cell phone emissions excite the brain cortex
3. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
4. Low level of extinction during ice age linked to adaptability
5. Improved statistical tools reveal many linked loci
6. Scientists at Galileo Pharmaceuticals confirm inflammatory response linked to glucose levels
7. Attacks of King George IIIs madness linked to key metabolism molecule
8. Gene controlling circadian rhythms linked to drug addiction
9. Physical and functional interaction of key cell growth molecules linked to cancer
10. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
11. Naturally occurring asbestos linked to lung cancer
Post Your Comments:
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 1New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 2New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 3New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 4Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 1Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 2Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 3Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 1Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 2Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 3Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 4Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 5Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 6Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 7Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 8Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 9Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 10Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 11
Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4
Other Biology Technology:PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 2PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 3PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 4PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 5Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 2Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 3Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 4Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 2Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 3Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 4